C-X-C motif chemokine 10 Antibodies

C-X-C motif chemokine 10 (CXCL10)

Chemotactic for monocytes and T-lymphocytes.

Binds to CXCR3.

.

Gene Information

Human
Gene Name:	CXCL10
Uniprot:	P02778
Entrez:	3627

Family

Belongs to:
intercrine alpha (chemokine CxC) family

Alternative Names

C7; chemokine (C-X-C motif) ligand 10; CRG2; CRG-2; CXCL10; gIP-10; IFI10; INP10; IP-10; mob-1; SCYB10

Molecular Weight

Mass (kDA):
10.881 kDA

Genomic Context

Human
Location:	4q21.1
Sequence:	4; NC_000004.12 (76021118..76023497, complement)

Subcellular Localizations

Secreted.

Diseases

• Inflammation
• Neoplasms
• Virus Diseases
• Malignant Neoplasms
• Autoimmune Reaction
• Infective Disorder
• Nervousness
• Tissue Adhesions
• Inflammatory Response
• Hepatitis
• Sclerosis
• Asthma
• Tumor Angiogenesis

• Multiple Sclerosis
• Autoimmune Diseases
• Diabetes Mellitus
• Innate Immune Response
• Cholangiocarcinoma
• Fibrosis
• Arthritis

Interacting Proteins

• CCL11
• CCL13
• CCL21
• CCL26
• CCL28

• CCL5
• CXCL12
• CXCL9
• DPP4
• PF4

Pathways

• Pathogenesis
• Immune Response
• Secretion
• Chemotaxis
• Inflammatory Response
• Chemokine Production
• Angiogenesis
• Cell Proliferation
• Cell Migration
• Cytokine Production
• Innate Immune Response
• Cell Death
• Localization

• Viral Replication
• Chemokine Secretion
• Cell Activation
• Cell Adhesion
• Hypersensitivity
• Leukocyte Migration
• Cell Growth

PTMs

• Phosphorylation
• Cleavage
• Acetylation
• Methylation
• Citrullination
• Deacetylation

• Dephosphorylation
• Ubiquitination
• Glycosylation
• Demethylation
• Prenylation
• Oxidation

• Palmitoylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CXCL10

Best Uses Of The CXCL10 Marker

The CXCL10 biomarker is a unique biomarker used to measure the severity of human African trypanosomiasis. It regulates immune pathways and the progression to thyroid cancer. It is however not widely understood what it is or how it can be used. Continue reading to find out more about the CXCL10 chemotherapy. It is used to diagnose and treat human African trypanosomiasis.

CXCL10 is a proinflammatory chemotherapy.

The therapeutic efficacy of CXCL10 is likely due to its role in immunostimulation of the immune system. Immune modulation of CXCL10 is a common method to boost the efficacy of vaccines. The CXCL10 gene also has synergistic effect on tumors, attracting immature antigen-presenting and activated T cells.

CXCL10, a member the CXC chemotactic and cytokine family which is extensively expressed in a variety of human diseases. It is crucial for leukocytes moving into inflamed tissue. Additionally, it can cause inflammation and can cause significant tissue damage. CXCL10 is one of the CXC Chemokines, which are a family of chemokines. It is a key factor in the development of angiogenesis in tumor cells.

It is interesting to note that CXCL10 has been found to be a chemoattractant that attracts T and NK cells. CXCL10 also is released in proinflammatory conditions by activated neutrophils as well as leukocytes. CXCL10 chemoattraction is crucial for Treg survival, however more research is required to discover how CXCL10 accumulates within the immune system.

A rise in the production of CXCL10 in the brain has been linked to a variety of neurodegenerative diseases, including Alzheimer's disease and amytrophic lateral MS, multiple sclerosis and human immunodeficiency virus encephalitis. These findings suggest that CXCL10 could be a possible therapeutic target for a range of diseases. This study highlights the importance of researching CXCL10 as a biomarker of cancer.

In mice in mice, fibrillar Ab stimulates primary microglia, and astrocyteswhich produce CXCL10. It also promotes the development of TNF-a. Fibrillar ab stimulates both microglia primary and astrocytes, which are both proinflammatory types. These chemokines that are proinflammatory, in addition to LPS and TNF-a, also play a role in the immune system.

It regulates the immune system

Boster Bio researchers discovered that CXCL10, a chemokine receptor that regulates immune pathways in the latest study. In the PTC immune microenvironment, this chemokine gets produced by cells and can be detected by the CXCL10 antibody. This marker was chosen for further research due to its significance in the immune response. We will now discuss the mechanisms that control this chemical.

The study also revealed that blocking the CXCL10/CXCR3 receptors by PDAC cells results in an increase in macrophages that are inflammatory and stimulates the process of fibrosis. When used in PanIN cells, it stopped the growth and progression of PDAC tumors. We are looking forward to investigating the mechanisms that underlie this new treatment. For more details, check out our entire press release.

Recent research revealed that CXCL10 is a strong biomarker of the renal system, and could be used to predict various diseases. It is not clear how this chemokine regulates immune pathways, but it may be a potential biomarker or therapeutic target for certain diseases. These results suggest that this chemokine might play a role in the development and progression of autoimmune conditions.

TCGA data is also used to identify the roles of DEGs within the PTC microenvironment. We have identified a substantial number of DEGs that regulate the immune response of PTC cells. The genes that are enriched in these pathways were identified using a Venn diagram. This suggests that CXCL10 could be a promising biomarker for further investigation of the immune response to PTC tumors.

Researchers found that blocking the CXCR3 pathway decreased the inflammatory response to immuneproteasome dysfunction. CXCR3 inhibitors could be a viable treatment option for patients suffering from this condition. CXCL9, CXCL10, and CXCL10 are potential drug targets in PRAAS. Boster Bio's CXCL10 marker regulates immune systems

It helps to prevent the development of thyroid cancer.

TWIST is involved in the METastatic procedure for thyroid cancer. The overexpression of TWIST was associated with a virulent thyroid cancer-related phenotypes, as Wang et al. RT-PCR was used to confirm this. CXCR4 levels in PTCs were higher than thyroid tissue. The higher levels were linked to metastasis.

The chemical receptor CCR3 was first discovered in renal cell carcinoma and only two studies have been conducted on the expression of CCR3 in thyroid cancer. Gonzales et. The study by Gonzales and al. revealed that CCR3 expression was significantly higher in PTC when it was studied by flow cytometry or immunohistochemistry. This study was similar to a paper published recently by Tang et. al. who utilized bioinformatics to aid in analysis of the data and discovered the exact same correlation.

Chemokines are soluble mediators regulate the behavior of cells. Thyroid cancer cells produce chemokine receptors that regulate the cell's behavior. A thorough review of thyroid tumor immunology will examine how these chemokine receptors control the tumor's microenvironment. Cancer-bearing thyroid cancers have a specific set of receptors for chemokine, while normal thyroid cells have an additional set. These receptors play a role on the disease's progression and response to immunotherapy.

The CXCL10 marker is associated with a low prognosis in patients with thyroid cancer. This can help guide the treatment of immunotherapy. This study will provide insight into the mechanism behind Thyroid cancer immunotherapy. It is possible that the CXCL10 marker will help predict the prognosis of patients suffering from thyroid cancer. It is also associated with HRD which is a frequent cause of thyroid disease.

In addition to CCR7 In addition to CCR7, the CXCL10 marker is also controlled by the CTLA-4 gene which is a chemokine receptor that is found on tumor cells. It is a major mediator of dendritic and lymphocyte cell trafficking. Lymph node metastasis can be associated with CCR7 expression in thyroid cancer. CCR7 expression is positively correlated with TPC-1 metastatic potency.

It is a unique biomarker for the severity of human African trypanosomiasis

Infections with Trypanosoma brucei (T. b. the brucei) occur in three stages: hemolymphatic the encephalitic stage, and the late-stage. The pro-inflammatory cytokines are elevated in the initial stages of the disease. Late-stage infections tend to be more counter-inflammatory. The stage of infection may be the reason for the differences.

The stage of disease is only determined by invasive procedures, such as the lumbar puncture. It's not always possible to determine this based on the clinical signs and symptoms. Because this procedure is so invasive, it requires experts to perform the examination. A new biomarker that can be used to assess the severity of disease is needed. It can help physicians determine the most appropriate treatment for a patient.

The use of immunopathological techniques to determine the severity of disease is essential to ensure the efficient control of the parasite. Cytokines such as IL-6 are essential in the fight against disease, but they cannot be used as biomarkers on their own. To enhance the efficacy of diagnostic tests, CXCL10 may be used together with other markers.

The study was financed by the National Institutes of Health and the Center for Disease Diagnosis and Research in Ghana. Dr. Mingli Liu, a Ph.D. student, received her Ph.D. from the Chinese Academy of Medical Sciences. Her current research interests include in the pathogenesis and treatment of severe malaria.

A recent study found that elevated CXCL10 levels in jejunal tissue correspond with parasite burden and histopathology. Furthermore, CXCL10 inhibits the immune response in AIDS patients, which can aid in the identification of a specific kind of malaria. Many researchers are examining the possibility of using CXCL10 as a biomarker to detect human African trypanosomiasis.

The study was conducted in accordance with the Declaration of Helsinki. All subjects, including children gave informed consent using written or oral information. Ethics-compliant consent forms were developed in both French and English. The forms were translated into local languages when needed. The study protocol was approved by the National Ethics Committees of the DRC and Cameroon and was carried out in line with the guidelines of the Ministry of Health's national sleeping sickness control program.